false
English
Catalog
2024 World Conference on Lung Cancer (WCLC) - Post ...
P2.11A.10 Impact of Baseline Glucocorticoid Use on ...
P2.11A.10 Impact of Baseline Glucocorticoid Use on the Efficacy of Immunoradiotherapy in NSCLC Patients with Brain Metastases
Back to course
Pdf Summary
The study examines the impact of baseline glucocorticoid (GCs) use on the efficacy of immunotherapy combined with intracranial radiotherapy in patients with non-small cell lung cancer (NSCLC) and brain metastases. GCs, often administered to manage cerebral edema, might reduce the effectiveness of such combination therapies due to their negative impact on immunotherapy.<br /><br />The researchers analyzed data from 62 NSCLC patients, categorizing them based on their baseline GCs usage into three groups: low (30 mg), medium (30-100 mg), and high (100 mg). The study aimed to understand how these GCs doses affected intracranial progression-free survival (iPFS), progression-free survival (PFS), and overall survival (OS).<br /><br />Results indicated that increased baseline use of GCs is linked to a reduced efficacy of the combination therapy, with high-dose GCs (100 mg) notably impairing survival outcomes. The study found that high baseline GCs doses negatively affected iPFS, PFS, and OS compared to lower doses. Cox proportional hazard models and propensity score matching (PSM) were employed to ensure the balance of variables and accurate assessment of survival outcomes.<br /><br />The study underscores the importance of considering the dose of glucocorticoids used in NSCLC patients with brain metastases undergoing immunotherapy and radiotherapy, advising cautious use of GCs to preserve the benefits of these treatments. This research contributes to better-informed clinical decisions regarding GC use to optimize therapeutic outcomes for affected patients.<br /><br />Funding for the study was provided by the CQMU Program for Youth Innovation in Future Medicine, the Kuanren Talents Program, and the China Postdoctoral Science Foundation.
Asset Subtitle
Yuan Peng
Meta Tag
Speaker
Yuan Peng
Topic
Metastatic NSCLC – Immunotherapy
Keywords
glucocorticoid
immunotherapy
intracranial radiotherapy
non-small cell lung cancer
brain metastases
baseline GCs
survival outcomes
Cox proportional hazard models
propensity score matching
clinical decisions
×
Please select your language
1
English
5
普通话
11
Dutch